1. Is the distribution agreement with HL pharma announced in November 2017 still valid? a. If so, how does MGC explain the use of the term 'exclusive' in the announcement of the distribution agreement with HL Pharma despite two other Australian pharmaceutical distribution companies that have been announced in May 2019 as being proposed to distribute MGC's pharmaceutical products within Australia? b. again, if the agreement is still valid, the announcement stated that they expected HL Pharma to begin selling Cannepil 'to the Australian market from early 2018.' Can MGC explain the delay?
2. Is the distribution agreement with A.M Mangion announced in September 2018 still valid and progressing? a. If so, when does MGC expect to begin sending shipments to A.M. Mangion?
3. In October 2017, MGC announced a '5-year Supply and Distribution Agreement with European pharmaceutical distributioncompany, Lenis'. Is this agreement still valid? a. If so, when does MGC expect to begin sending shipments to Lenis?
MXC Price at posting:
4.9¢ Sentiment: None Disclosure: Held
